These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 17894778)

  • 1. Pharmacological chaperone therapy for lysosomal storage disorders - leveraging aspects of the folding pathway to maximize activity of misfolded mutant proteins.
    Fan JQ
    FEBS J; 2007 Oct; 274(19):4943. PubMed ID: 17894778
    [No Abstract]   [Full Text] [Related]  

  • 2. A counterintuitive approach to treat enzyme deficiencies: use of enzyme inhibitors for restoring mutant enzyme activity.
    Fan JQ
    Biol Chem; 2008 Jan; 389(1):1-11. PubMed ID: 18095864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity.
    Fan JQ
    Trends Pharmacol Sci; 2003 Jul; 24(7):355-60. PubMed ID: 12871668
    [No Abstract]   [Full Text] [Related]  

  • 4. Stimulation of proteasome by all-trans-retinoic acid: a novel therapeutic approach for lysosomal storage diseases?
    Geroldi D; Emanuele E; Arra M
    Med Hypotheses; 2007; 68(4):913. PubMed ID: 17097825
    [No Abstract]   [Full Text] [Related]  

  • 5. Stop-codon read-through for patients affected by a lysosomal storage disorder.
    Brooks DA; Muller VJ; Hopwood JJ
    Trends Mol Med; 2006 Aug; 12(8):367-73. PubMed ID: 16798086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological small molecules for the treatment of lysosomal storage disorders.
    Smid BE; Aerts JM; Boot RG; Linthorst GE; Hollak CE
    Expert Opin Investig Drugs; 2010 Nov; 19(11):1367-79. PubMed ID: 20942596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacoperone drugs: targeting misfolded proteins causing lysosomal storage-, ion channels-, and G protein-coupled receptors-associated conformational disorders.
    Hou ZS; Ulloa-Aguirre A; Tao YX
    Expert Rev Clin Pharmacol; 2018 Jun; 11(6):611-624. PubMed ID: 29851355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemical and biological approaches synergize to ameliorate protein-folding diseases.
    Mu TW; Ong DS; Wang YJ; Balch WE; Yates JR; Segatori L; Kelly JW
    Cell; 2008 Sep; 134(5):769-81. PubMed ID: 18775310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological chaperones for enzyme enhancement therapy in genetic diseases.
    Aymami J; Barril X; Rodríguez-Pascau L; Martinell M
    Pharm Pat Anal; 2013 Jan; 2(1):109-24. PubMed ID: 24236974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Storage solutions: treating lysosomal disorders of the brain.
    Jeyakumar M; Dwek RA; Butters TD; Platt FM
    Nat Rev Neurosci; 2005 Sep; 6(9):713-25. PubMed ID: 16049428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carbohydrate-Processing Enzymes of the Lysosome: Diseases Caused by Misfolded Mutants and Sugar Mimetics as Correcting Pharmacological Chaperones.
    Stütz AE; Wrodnigg TM
    Adv Carbohydr Chem Biochem; 2016; 73():225-302. PubMed ID: 27816107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological chaperone therapy for lysosomal storage diseases.
    Parenti G; Moracci M; Fecarotta S; Andria G
    Future Med Chem; 2014 Jun; 6(9):1031-45. PubMed ID: 25068986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological chaperones as therapeutics for lysosomal storage diseases.
    Boyd RE; Lee G; Rybczynski P; Benjamin ER; Khanna R; Wustman BA; Valenzano KJ
    J Med Chem; 2013 Apr; 56(7):2705-25. PubMed ID: 23363020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory watch: enhanced chance of success for protein replacement therapies.
    Crunkhorn S
    Nat Rev Drug Discov; 2013 Jun; 12(6):414. PubMed ID: 23722335
    [No Abstract]   [Full Text] [Related]  

  • 15. Active-site-specific chaperone therapy for Fabry disease. Yin and Yang of enzyme inhibitors.
    Fan JQ; Ishii S
    FEBS J; 2007 Oct; 274(19):4962-71. PubMed ID: 17894781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclodextrin-based iminosugar click clusters: the first examples of multivalent pharmacological chaperones for the treatment of lysosomal storage disorders.
    Decroocq C; Rodríguez-Lucena D; Ikeda K; Asano N; Compain P
    Chembiochem; 2012 Mar; 13(5):661-4. PubMed ID: 22344719
    [No Abstract]   [Full Text] [Related]  

  • 17. The cell biology of lysosomal storage disorders.
    Futerman AH; van Meer G
    Nat Rev Mol Cell Biol; 2004 Jul; 5(7):554-65. PubMed ID: 15232573
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of lysosomal storage disorders.
    Mehta AB; Lewis S; Laverey C
    BMJ; 2003 Aug; 327(7413):462-3. PubMed ID: 12946951
    [No Abstract]   [Full Text] [Related]  

  • 19. Lysosomal storage diseases market.
    Werber Y
    Nat Rev Drug Discov; 2004 Jan; 3(1):9-10. PubMed ID: 14756143
    [No Abstract]   [Full Text] [Related]  

  • 20. Therapeutic applications of imino sugars in lysosomal storage disorders.
    Butters TD; Dwek RA; Platt FM
    Curr Top Med Chem; 2003; 3(5):561-74. PubMed ID: 12570866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.